Compare ACRV & NTIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRV | NTIC |
|---|---|---|
| Founded | 2018 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.7M | 77.9M |
| IPO Year | 2022 | N/A |
| Metric | ACRV | NTIC |
|---|---|---|
| Price | $2.52 | $7.40 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.67 | N/A |
| AVG Volume (30 Days) | ★ 531.8K | 41.2K |
| Earning Date | 11-13-2025 | 01-07-2026 |
| Dividend Yield | N/A | ★ 0.54% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.00 |
| Revenue | N/A | ★ $84,234,474.00 |
| Revenue This Year | N/A | $7.89 |
| Revenue Next Year | $805.20 | N/A |
| P/E Ratio | ★ N/A | $4,088.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.05 | $6.75 |
| 52 Week High | $8.00 | $14.75 |
| Indicator | ACRV | NTIC |
|---|---|---|
| Relative Strength Index (RSI) | 58.65 | 45.52 |
| Support Level | $2.44 | $7.35 |
| Resistance Level | $2.73 | $7.52 |
| Average True Range (ATR) | 0.17 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 63.16 | 52.27 |
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company.